Payment overview · 2025
General Payments
$354.95
21 reported records · 6 companies
Healthcare provider profile · identity verified
Jason Anthony Carnes, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HUNTERSVILLE, NC · NPI 1023278793
Verified facts
What the public records show
CMS Open Payments records show Jason Anthony Carnes, MD received $354.95 in general payments during 2025 across 21 reported records.
PFIZER INC. accounted for 56.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $200.51 | 56.5% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.16 | 16.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.63 | 10.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.97 | 7.0% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $19.44 | 5.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.24 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $354.95 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $200.51 | 14 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $200.51 | 14 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $57.16 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $57.16 | 2 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 17 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 11 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 96 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
84 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
96 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
214 | 44 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 695 | 194 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 559 | 168 |
| Omeprazole | Omeprazole | 494 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 464 | 129 |
| Lisinopril | Lisinopril | 390 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 350 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 283 | 80 |
| Losartan Potassium | Losartan Potassium | 259 | 74 |
| Simvastatin | Simvastatin | 216 | 57 |
| Eliquis | Apixaban | 214 | 44 |
| Trazodone Hcl | Trazodone Hcl | 179 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 175 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 47 |
| Montelukast Sodium | Montelukast Sodium | 167 | 47 |
| Gabapentin | Gabapentin | 166 | 44 |
| Sertraline Hcl | Sertraline Hcl | 157 | 42 |
| Metformin Hcl | Metformin Hcl | 152 | 42 |
| Ozempic | Semaglutide | 148 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 144 | 41 |
| Alprazolam | Alprazolam | 143 | 29 |
| Metformin Hcl Er | Metformin Hcl | 141 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 40 |
| Carvedilol | Carvedilol | 122 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 32 |
| Allopurinol | Allopurinol | 121 | 35 |
| Glipizide | Glipizide | 116 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 35 |
| Meloxicam | Meloxicam | 112 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 31 |
| Jardiance | Empagliflozin | 107 | 28 |
| Donepezil Hcl | Donepezil Hcl | 105 | 30 |
| Atenolol | Atenolol | 103 | 30 |
| Tramadol Hcl | Tramadol Hcl | 103 | 22 |
| Furosemide | Furosemide | 102 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 20 |
| Ezetimibe | Ezetimibe | 101 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 23 |
| Clonazepam | Clonazepam | 96 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 96 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 22 |
| Finasteride | Finasteride | 84 | 27 |
| Synthroid | Levothyroxine Sodium | 84 | 21 |
| Famotidine | Famotidine | 82 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 82 | 19 |
| Celecoxib | Celecoxib | 70 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 16 |
| Lorazepam | Lorazepam | 66 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 19 |
| Prednisone | Prednisone | 64 | 41 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 16 |
| Warfarin Sodium | Warfarin Sodium | 60 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 17 |
| Bupropion Xl | Bupropion Hcl | 54 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 29 |
| Cephalexin | Cephalexin | 49 | 30 |
| Potassium Chloride | Potassium Chloride | 48 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 12 |
| Mirtazapine | Mirtazapine | 46 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 42 | 41 |
| Diazepam | Diazepam | 39 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Lovastatin | Lovastatin | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 21 |
| Spironolactone | Spironolactone | 35 | 14 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 28 |
| Methylprednisolone | Methylprednisolone | 34 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 23 |
| Glimepiride | Glimepiride | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 13 |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Colchicine | Colchicine | 20 | 11 |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 11 |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Testosterone | Testosterone | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Alprazolam Er | Alprazolam | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $354.95 · 21 records | PFIZER INC. | AREXVY, ETERNA, ImmunoCAP, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error